An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sl ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.

In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...